Future-Proofing the Pharma Customer & Supplier Relationship

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

Continuous adaption
Evolving US tariff/trade policy is but one of the many variables that bio/pharmaceutical companies and their suppliers are facing. Global supply chains are always subject to geopolitical uncertainties, fluctuating economic conditions, and changes in trade and government policies, but the pace of that change has accelerated. Add to that the base challenge of increased product and supply chain complexity in the industry, and the need for bio/pharma companies and their suppliers to adapt is ever more important for supply assurance.

Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer

An executive panel at the DCAT Week program, Future-Proofing the Pharma Customer–Supplier Relationship, will share lessons learned, best practices, and innovative ways on how they are collaborating to enhance supply-chain visibility and resilience, mitigate risk, and optimize supply planning now and for what may lie ahead.

Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb

Participating in the panel of are:  Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer; Emad Abdelsadek, Vice President, Sales, EMEA, BD Biopharma Systems; Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb; and Sara Henneman, Vice President and General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific. The panel will be moderated by Vishal Bhandari, Partner, Healthcare & Life Sciences Practice, Americas, Kearney.

The program, Future-Proofing the Pharma Customer–Supplier Relationship, is part of DCAT Week, the premier gathering for companies engaged in the global bio/pharmaceutical business ecosystem, hosted by the Drug, Chemical & Associated Technologies Association (DCAT). DCAT Week will be held March 23–26, 2026, in New York. The program, Future-Proofing the Pharma Customer–Supplier Relationship, will be held on Tuesday March 24, 2026, 11:00 AM–12:00 PM. Further information, including how to register, may be found here. The program is exclusive to DCAT Member Companies.

Recent Feature Articles

What is Top of the Industry’s Sustainability Agenda in 2026?

By
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.

Change, Change, & Change: The Pharma Industry’s Outlook & Response

By
The bio/pharma industry faces geopolitical uncertainties, fluid trade conditions, and greater product and supply-chain complexity. What lies ahead for bio/pharma companies and suppliers? An outlook for the industry. 

AI: The State of the State in Supply Management 

By
AI and digitalization hold great potential in transforming business functions, but where do they really stand in supply management? An executive panel at DCAT Week will share their perspectives on how AI may transform how pharma companies and their suppliers do business.

What’s in Store for Pharma in 2026 & Beyond?

By
Evolving tariff/trade policy, US drug pricing reforms, and a changing global landscape are contributing to an uncertain environment. A DCAT Week education program, featuring experts from IQVIA, will provide in-depth insights on pharma industry performance.